Allarity Therapeutics, Inc. engages in the development of drugs for personalized treatment of cancer guided by its proprietary Drug Response Predictor (DRP) technology. The company is headquartered in Boston, Massachusetts and currently employs 6 full-time employees. The company went IPO on 2021-12-21. The company is focused on development of stenoparib, a PARP/tankyrase inhibitor for advanced ovarian cancer patients, using its DRP technology to develop a companion diagnostic that can be used to select those patients expected to derive clinical benefit from stenoparib. Its therapeutic candidate, stenoparib, is a dual inhibitor of the key DNA damage repair enzyme PARP, as well as Tankyrases, critical enzymes involved in the WNT signaling pathway commonly activated in many cancers. Inhibition of key DNA damage repair enzymes, such as PARP, has clinically demonstrated to be therapeutically beneficial in the treatment of cancers (ovarian cancers). The DRP method builds on the comparison of sensitive vs. resistant human cancer cell lines, including transcriptomic information from cell lines, combined with clinical tumor biology filters and prior clinical trial outcomes.
Follow-Up Questions
¿Quién es el CEO de Allarity Therapeutics Inc?
Mr. Thomas Jensen es el Chief Executive Officer de Allarity Therapeutics Inc, se unió a la empresa desde 2020.
¿Qué tal es el rendimiento del precio de la acción ALLR?
El precio actual de ALLR es de $1.47, ha increased un 2.08% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Allarity Therapeutics Inc?
Allarity Therapeutics Inc pertenece a la industria Biotechnology y el sector es Health Care
¿Cuál es la capitalización bursátil de Allarity Therapeutics Inc?
La capitalización bursátil actual de Allarity Therapeutics Inc es $21.4M
¿Es Allarity Therapeutics Inc una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 3 analistas han realizado calificaciones de análisis para Allarity Therapeutics Inc, incluyendo 2 fuerte compra, 4 compra, 1 mantener, 0 venta, y 2 fuerte venta